Introduction: Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterized by increased pulmonary vascular resistance (PVR), right ventricular failure, and premature mortality (1). Despite advances with endothelin receptor antagonists (ERAs), phosphodiesterase type 5 inhibitors (PDE5i), and prostacyclin analogues, many patient
Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure
150 Reached
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Patient with History of Atrial Fibrillation
519 Reached3 Likes
FOURIER Trial: Efficacy of Evolocumab in Managing Cardiovascular Events
563 Reached3 Comments